- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01351428
Goal-Directed Therapy in Pregnant Women at High Risk of Developing Preeclampsia
Non-invasive Hemodynamic Monitoring and Goal-Directed Therapy in Pregnant Women at High Risk of Developing Preeclampsia
Preeclampsia is associated with significant maternal and fetal morbidity and mortality. Early identification and subsequent management of patients at risk of developing preeclampsia presents an ongoing challenge in prenatal care. Some at risk pregnancies may be identified from:
- serum screening abnormalities in the first or second trimester
- placental shape and texture at the 18-20 anatomical ultrasound
- uterine artery blood flow.
Early identification and effective treatment of patients would permit the safe completion of the pregnancy for the mother and infant. Recent advances in non-invasive cardiovascular monitoring have enabled the study of maternal hemodynamics in normal and at-risk pregnancies. This study hopes to identify the earliest significant changes in maternal hemodynamics which may allow targeted therapeutic interventions in patients at high risk of developing preeclampsia.
The hypothesis of this study is that systemic vascular resistance rises during the pre-clinical phase of preeclampsia and this can be captured using non invasive bioreactance technology. Treatment of the abnormally high vascular tone may decrease the severity and postpone the onset of clinical disease.
연구 개요
상세 설명
Invasive hemodynamic techniques have long identified significant increases in heart rate (HR), blood volume, left ventricular end-diastolic volume (LVEDV), stroke volume (SV) and cardiac output (CO) during the first and second trimesters of pregnancy. In normal pregnancy, CO increases from as early as 5 weeks gestation, with a 30-40% increase by the end of the first trimester of pregnancy. Cardiac output continues to rise throughout the second trimester until it reaches a level approximately 50% greater than that of non-pregnant women. Cardiac output slightly decreases during the third trimester. Despite these changes, maternal blood pressure (BP) still falls due to a large reduction in systemic vascular resistance (SVR) from systemic vasodilatation and the formation of a low-resistance utero-placental circulation. Systemic vascular resistance falls during early gestation, reaching its nadir (35% decline) at 20 weeks gestation, and rises during late pregnancy.
Transthoracic bioreactance is a newer technique of non-invasive continuous cardiac output monitoring. It is based on an analysis of relative phase shifts of oscillating currents that occur when this current traverses the thoracic cavity, as opposed to the traditional bioimpedance-based system, which rely only on measured changes in signal amplitude. Unlike bioimpedance, bioreactance-based non-invasive CO measurement does not use the static impedance and does not depend on the distance between the electrodes for the calculations of SV and CO, which significantly reduces the uncertainty in the result. Moreover, its readings were shown to correlate well with results derived from pulmonary artery catheter derived measurement of cardiac output. In addition, it has also been shown that the non-invasive cardiac output measurement (NICOM®) system has acceptable accuracy, precision and responsiveness for CO monitoring in patients experiencing a wide range of circulatory situations and has recently been used in the obstetric population.
The purpose of this study is to use non-invasive cardiac output monitoring to capture the earliest inappropriate rise in SVR during the pre clinical phase of disease, in patients at high risk of developing preeclampsia, as predicted by the placenta profile. In case an increase in SVR is identified, the purpose of this study is to implement a goal-directed therapy in an attempt to decrease the severity, and postpone the onset of clinical disease.
The hypothesis of this study is that the increases in SVR detected during the pre-clinical phase of preeclampsia can be treated with a goal directed therapy without fetal compromise and that this intervention may improve maternal and fetal/neonatal outcome.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G1X5
- Mount Sinai Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Risk factors for preeclampsia/IUGR - medical or obstetric
- Abnormal uterine artery Doppler
- Two of the following:
Abnormal placental biochemistry Abnormal placental shape Abnormal placental texture
Exclusion Criteria:
- Multifetal pregnancy
- Fetal abnormality, including nuchal translucency more than 3mm at 12 weeks
- Preterm labor/pprom/bleeding/rescue cerclage (excluding elective 12 week prophylactic cerclage)
- Type 1 diabetes mellitus
- Heparin use
- Chronic hypertension on treatment before 20 weeks
- Documented chronic renal disease
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: NICOM group
Vasodilator therapy begins when SVR increases by 20% or greater than baseline.
Therapy is titrated according to hemodynamic profile and clinical signs and symptoms.
|
30-60 mg, twice daily
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Systemic vascular resistance
기간: 20-22, 24-26, 28, 30-32 and 36 weeks gestational age
|
Systemic vascular resistance is measured at the above time points, and more frequently at the discretion of the attending obstetrician.
|
20-22, 24-26, 28, 30-32 and 36 weeks gestational age
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Maximum change in maternal blood pressure
기간: 20-22, 24-26, 28, 30-32 and 36 weeks gestational age
|
Blood pressure is taken on the NICOM at the above time points, and more frequently at obstetric appointments in between.
|
20-22, 24-26, 28, 30-32 and 36 weeks gestational age
|
Gestational age at delivery
기간: 25-41 weeks gestational age
|
25-41 weeks gestational age
|
|
Fetal weight at delivery
기간: 25-41 weeks gestational age
|
25-41 weeks gestational age
|
|
Gestational age at time of first hospitalization
기간: 25-41 weeks gestational age
|
25-41 weeks gestational age
|
|
Gestational age at peak maternal blood pressure
기간: 20-41 weeks
|
20-41 weeks
|
|
Gestational age at which steroids are administered
기간: 25-41 weeks gestational age
|
25-41 weeks gestational age
|
|
Serum s-Flt and PlGF levels
기간: 12-41 weeks gestational age
|
12-41 weeks gestational age
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 10-03
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Nifedipine에 대한 임상 시험
-
SocraTec R&D GmbHSocraMetrics GmbH완전한
-
Shanghai Shyndec Pharmaceutical Co., Ltd.알려지지 않은
-
Shanghai Shyndec Pharmaceutical Co., Ltd.완전한
-
Hasten Biopharmaceutical Co., Ltd.모병
-
Food and Drug Administration (FDA)BioPharma Services, Inc완전한